These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10398105)

  • 1. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers.
    Bosserhoff AK; Moser M; Hein R; Landthaler M; Buettner R
    J Pathol; 1999 Mar; 187(4):446-54. PubMed ID: 10398105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
    Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
    Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas.
    Gong J; Chen N; Zhou Q; Yang B; Wang Y; Wang X
    J Clin Pathol; 2005 Oct; 58(10):1081-5. PubMed ID: 16189155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.
    Hau P; Apfel R; Wiese P; Tschertner I; Blesch A; Bogdahn U
    Anticancer Res; 2002; 22(2A):577-83. PubMed ID: 12014625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micro-anatomy related antigen expression in melanocytic lesions.
    Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
    J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cadherin expression in melanocytic naevi and malignant melanomas.
    Cowley GP; Smith ME
    J Pathol; 1996 Jun; 179(2):183-7. PubMed ID: 8758211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression patterns of S100 proteins in melanocytes and melanocytic lesions.
    Petersson S; Shubbar E; Enerbäck L; Enerbäck C
    Melanoma Res; 2009 Aug; 19(4):215-25. PubMed ID: 19521263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA.
    Chen N; Gong J; Chen X; Xu M; Huang Y; Wang L; Geng N; Zhou Q
    Melanoma Res; 2009 Apr; 19(2):87-93. PubMed ID: 19190520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression patterns in melanocytic cells: candidate markers for early stage and malignant transformation.
    Meije CB; Hakvoort TB; Swart GW; Westerhof W; Lamers WH; Das PK
    J Pathol; 2002 Jan; 196(1):51-8. PubMed ID: 11748642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
    Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
    Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
    Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
    Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
    Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of melastatin mRNA expression in melanocytic tumors.
    Deeds J; Cronin F; Duncan LM
    Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood.
    de Vries TJ; Fourkour A; Punt CJ; Diepstra H; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 Nov; 81(6):1066-70. PubMed ID: 10576666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
    Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
    J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens.
    Perez RP; Zhang P; Bosserhoff AK; Buettner R; Abu-Hadid M
    Hum Pathol; 2000 Nov; 31(11):1381-8. PubMed ID: 11112213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma.
    Nürnberg W; Tobias D; Otto F; Henz BM; Schadendorf D
    J Pathol; 1999 Dec; 189(4):546-51. PubMed ID: 10629556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MIA, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
    Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.